Contributors |
|
xiii | |
Preface |
|
xv | |
|
Section VI Statistical Methodologies |
|
|
|
1 Imputation of Area-Level Covariates by Registry Linking |
|
|
3 | (20) |
|
|
|
|
3 | (1) |
|
2 Prediction of Unknown Locations |
|
|
4 | (3) |
|
|
4 | (1) |
|
2.2 Classified Mixed Model Prediction |
|
|
5 | (1) |
|
2.3 Incorporating Spatial Structure |
|
|
6 | (1) |
|
2.4 Robust Classified Predictions |
|
|
7 | (1) |
|
|
7 | (4) |
|
3.1 Simulation 1---Spatially Correlated Locations: Less Separable Clusters |
|
|
7 | (2) |
|
3.2 Simulation 2---Spatially Correlated Locations: More Separable Location Clusters |
|
|
9 | (1) |
|
3.3 Simulations 3a and 3b |
|
|
10 | (1) |
|
4 Predicting Community Characteristics for Colon Cancer Patients From the Florida Cancer Data System |
|
|
11 | (6) |
|
4.1 Clustering of Census Tracts Adds Robustness to Predictions |
|
|
15 | (2) |
|
|
17 | (6) |
|
|
20 | (1) |
|
|
20 | (3) |
|
2 Asymptotic Approaches to Discovering Cancer Genomic Signatures |
|
|
23 | (14) |
|
|
|
|
23 | (3) |
|
1.1 Cancer Models and Next Generation Sequencing |
|
|
23 | (2) |
|
1.2 Our Current Contribution |
|
|
25 | (1) |
|
|
26 | (3) |
|
|
26 | (1) |
|
|
26 | (3) |
|
2.3 Functional Annotation |
|
|
29 | (1) |
|
|
29 | (3) |
|
4 Summary and Conclusions |
|
|
32 | (5) |
|
|
33 | (1) |
|
Appendix. Proof of Theorem 1 |
|
|
33 | (2) |
|
|
35 | (2) |
|
3 Emerging Statistical Methodologies in the Field of Microbiome Studies |
|
|
37 | (18) |
|
|
|
38 | (1) |
|
2 Microbial Sequencing Technologies and Associated Data |
|
|
39 | (2) |
|
2.1 Targeted Amplicon Sequencing |
|
|
39 | (1) |
|
2.2 Metagenomic Sequencing |
|
|
40 | (1) |
|
3 Statistical Methodologies for Microbiome Studies |
|
|
41 | (6) |
|
3.1 Diversity of Microbial Communities |
|
|
41 | (1) |
|
3.2 Compositional Analysis of Microbiome |
|
|
42 | (2) |
|
3.3 Variable Selection in Microbiome Association Studies |
|
|
44 | (1) |
|
3.4 Prediction of Metagenomes From 16S Data |
|
|
45 | (1) |
|
3.5 Statistical Learning in Microbiome Studies |
|
|
45 | (2) |
|
3.6 Computational Tools for Microbiome Analysis |
|
|
47 | (1) |
|
4 Discussion and Future Directions |
|
|
47 | (8) |
|
|
49 | (6) |
|
Section VII Advanced Mathematical Methods |
|
|
|
4 Reaction--Diffusion Equations and Their Application on Bacterial Communication |
|
|
55 | (38) |
|
|
|
55 | (1) |
|
2 Bacterial Communication and Some Basic Mathematical Model Approaches |
|
|
56 | (10) |
|
2.1 Basic Model With Positive Feedback Loop |
|
|
58 | (4) |
|
2.2 Including Bacterial Population Growth |
|
|
62 | (1) |
|
2.3 Including a Negative Feedback and Delay |
|
|
63 | (2) |
|
2.4 Outlook: Quorum Sensing in Space |
|
|
65 | (1) |
|
3 Introduction of Reaction--Diffusion Equations |
|
|
66 | (6) |
|
|
66 | (3) |
|
3.2 Adding the Reaction to the Diffusion |
|
|
69 | (1) |
|
3.3 Initial and Boundary Conditions |
|
|
69 | (1) |
|
|
70 | (1) |
|
3.5 Existence and Uniqueness of Solutions |
|
|
71 | (1) |
|
4 Reaction--Diffusion Equations and Quorum Sensing |
|
|
72 | (17) |
|
4.1 Working With Continuous Bacterial Distributions |
|
|
72 | (1) |
|
4.2 Traveling Wave Approach |
|
|
73 | (5) |
|
4.3 Models for Single Cells |
|
|
78 | (1) |
|
4.4 Approximate Equations for Point Sources |
|
|
78 | (3) |
|
4.5 Dynamic Model for Single Cells in Space |
|
|
81 | (8) |
|
|
89 | (4) |
|
|
90 | (3) |
|
5 Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling |
|
|
93 | (28) |
|
|
|
|
94 | (1) |
|
|
94 | (1) |
|
|
95 | (2) |
|
3.1 Global Epidemiology of HCV |
|
|
95 | (1) |
|
3.2 Transmission Routes for HCV |
|
|
96 | (1) |
|
3.3 Epidemiology of HCV in Key Populations |
|
|
96 | (1) |
|
4 HCV Screening, Treatment, and Prevention |
|
|
97 | (4) |
|
4.1 HCV Screening and Diagnosis |
|
|
97 | (1) |
|
|
98 | (1) |
|
4.3 HCV Prevention Strategies |
|
|
99 | (2) |
|
5 Role of Epidemic Modeling in Public Health |
|
|
101 | (1) |
|
6 Modeling HCV Treatment as Prevention |
|
|
101 | (5) |
|
7 Cost-Effectiveness Modeling in HCV |
|
|
106 | (8) |
|
7.1 Role of Cost-Effectiveness Modeling Including Prevention Benefits |
|
|
106 | (1) |
|
7.2 Evaluating the Cost-Effectiveness of HCV Treatment for PWID |
|
|
107 | (1) |
|
7.3 Overall Aim and Methodology |
|
|
107 | (7) |
|
7.4 Cost-Effectiveness Findings |
|
|
114 | (1) |
|
8 Conclusions and Public Health Challenges |
|
|
114 | (7) |
|
|
117 | (4) |
|
6 Mathematical Modeling of Mass Screening and Parameter Estimation |
|
|
121 | (34) |
|
|
|
1 Theoretical Framework of Mass Screening |
|
|
122 | (2) |
|
2 Mathematical Modeling of Mass Screening |
|
|
124 | (11) |
|
2.1 Basic Framework of the Mass Screening Model |
|
|
124 | (5) |
|
2.2 Demography of Human Population |
|
|
129 | (3) |
|
2.3 Theory of Mass Screening |
|
|
132 | (1) |
|
2.4 Stages of Cancer Progression |
|
|
132 | (1) |
|
2.5 Survival Rates of Different Stages |
|
|
133 | (1) |
|
|
134 | (1) |
|
3 Simulation: Breast Cancer in Japan |
|
|
135 | (16) |
|
3.1 Overview of Demography and Breast Cancer Epidemiology in Japan |
|
|
135 | (5) |
|
3.2 Model Building: The Framework of Breast Cancer Model Based on Observed Data |
|
|
140 | (4) |
|
3.3 Estimation of Transition Parameters |
|
|
144 | (4) |
|
3.4 Results of Simulation |
|
|
148 | (3) |
|
3.5 Characteristics of the Most Beneficial Mass Screening |
|
|
151 | (1) |
|
|
151 | (4) |
|
|
153 | (1) |
|
|
153 | (1) |
|
|
154 | (1) |
|
7 Inferring Patterns, Dynamics, and Model-Based Metrics of Epidemiological Risks of Neglected Tropical Diseases |
|
|
155 | (30) |
|
|
|
155 | (5) |
|
|
158 | (1) |
|
|
158 | (1) |
|
1.3 Modeling Neglected Vector-Borne Diseases |
|
|
159 | (1) |
|
|
160 | (20) |
|
2.1 Mapping and Relational Modeling of NTDs |
|
|
160 | (1) |
|
2.2 Securing Data and Empirical Information for Modeling NTDs |
|
|
160 | (2) |
|
2.3 Dynamical Modeling of NTDs |
|
|
162 | (18) |
|
|
180 | (5) |
|
|
181 | (4) |
|
8 Theory and Modeling for Time Required to Vaccinate a Population in an Epidemic |
|
|
185 | (24) |
|
|
|
|
|
185 | (2) |
|
|
187 | (2) |
|
3 Spatial Spread Through Convolution |
|
|
189 | (7) |
|
|
196 | (6) |
|
|
202 | (7) |
|
Appendix. Generalization of the Time Function |
|
|
202 | (3) |
|
|
205 | (4) |
|
Section VIII Public Health and Epidemic Data Modeling |
|
|
|
9 Frailty Models in Public Health |
|
|
209 | (40) |
|
|
|
209 | (1) |
|
|
210 | (1) |
|
3 Consequences of Ignoring Frailty |
|
|
211 | (3) |
|
4 Identifiability of Frailty Model |
|
|
214 | (1) |
|
|
215 | (1) |
|
6 General Shared Frailty Model |
|
|
216 | (2) |
|
7 Shared Gamma Frailty Model |
|
|
218 | (1) |
|
|
219 | (2) |
|
8.1 Generalized Log-Logistic Distribution |
|
|
219 | (1) |
|
8.2 Generalized Weibull Distribution |
|
|
220 | (1) |
|
|
221 | (1) |
|
10 Likelihood Specification and Bayesian Estimation of Parameters |
|
|
222 | (2) |
|
11 Analysis of Kidney Infection Data |
|
|
224 | (9) |
|
|
233 | (16) |
|
12.1 Correlated Frailty Model |
|
|
233 | (4) |
|
12.2 Frailty Models Based on Reversed Hazard Rate |
|
|
237 | (2) |
|
12.3 Frailty Models Based on Additive Hazard |
|
|
239 | (3) |
|
|
242 | (5) |
|
|
247 | (2) |
|
10 Structural Nested Mean Models or History-Adjusted Marginal Structural Models for Time-Varying Effect Modification: An Application to Dental Data |
|
|
249 | (26) |
|
|
|
250 | (2) |
|
2 Problem, Notation, and Definitions |
|
|
252 | (4) |
|
|
253 | (2) |
|
|
255 | (1) |
|
3 Detailed Description of SNMMs |
|
|
256 | (3) |
|
3.1 SNMMs for End of Study Outcome Measurement |
|
|
256 | (1) |
|
3.2 Estimating the Intermediate Causal Effects for Bivariate Point Treatment and End of Study Outcome |
|
|
257 | (1) |
|
3.3 SNMMs for Time-Varying Outcomes |
|
|
258 | (1) |
|
3.4 Estimating the Intermediate Causal Effects for Time-Varying Outcomes |
|
|
258 | (1) |
|
3.5 Counterfactual Creation and Blip Function |
|
|
259 | (1) |
|
4 History-Adjusted Marginal Structural Models |
|
|
259 | (2) |
|
4.1 Creation of Inverse Probability Treatment Weight, Referred to as Treatment Model |
|
|
260 | (1) |
|
|
261 | (1) |
|
5 Analysis of the Effect of Periodontal Treatment on Arterial Stiffness |
|
|
261 | (7) |
|
|
261 | (5) |
|
5.2 Simulation Data Set 2 |
|
|
266 | (2) |
|
|
268 | (1) |
|
6.1 Strengths and Limitations of the SNMM Models |
|
|
268 | (1) |
|
6.2 Strengths and Limitations of the IPTW HA-MSM |
|
|
268 | (1) |
|
|
269 | (6) |
|
A.1 STATA Code Used in Simulation 1 and Generating Tables 1 and 2 |
|
|
269 | (2) |
|
|
271 | (4) |
|
11 Conditional Growth Models: An Exposition and Some Extensions |
|
|
275 | (26) |
|
|
|
1 Introduction: The Problem to Be Addressed |
|
|
275 | (1) |
|
2 The New Delhi Birth Cohort Study |
|
|
276 | (1) |
|
3 Conditional Growth Models |
|
|
276 | (5) |
|
|
276 | (2) |
|
3.2 Data Checking and Choices in Model Formulation |
|
|
278 | (1) |
|
3.3 An Extension Using Height and Weight Measures Simultaneously |
|
|
279 | (1) |
|
3.4 An Extension Using Height, Weight, and Skinfold Thickness |
|
|
280 | (1) |
|
3.5 An Extension Using the Reversal of Time |
|
|
280 | (1) |
|
3.6 Selection of Suitable Age Intervals |
|
|
281 | (1) |
|
4 Descriptive Data and Traditional Analyses |
|
|
281 | (6) |
|
|
281 | (1) |
|
4.2 Choice of Age Intervals |
|
|
281 | (5) |
|
|
286 | (1) |
|
5 Conditional Models Applied to the New Delhi Birth Cohort Study Data |
|
|
287 | (6) |
|
5.1 Models in Height, Weight, and Body Mass Index Separately |
|
|
288 | (1) |
|
5.2 Models for Height and Weight Simultaneously |
|
|
288 | (3) |
|
5.3 Models That Reverse Time |
|
|
291 | (2) |
|
6 Strengths and Weaknesses of the Conditional Growth Model: Conclusions |
|
|
293 | (8) |
|
6.1 These Models Are Limited to Internal Comparisons |
|
|
293 | (1) |
|
|
293 | (3) |
|
6.3 Analogies With the Classical "Age, Period, Cohort" Problem |
|
|
296 | (1) |
|
6.4 Other Epidemiological Principles |
|
|
296 | (1) |
|
6.5 Linear Spline Mixed Models |
|
|
297 | (1) |
|
6.6 The Markov Principle and Regression to the Mean |
|
|
298 | (1) |
|
6.7 Public Health Relevance of the Results Reported Here |
|
|
298 | (1) |
|
6.8 Summary of the Conditional Growth Models |
|
|
299 | (1) |
|
|
299 | (1) |
|
|
299 | (2) |
|
12 Parametric Model to Predict H1N1 Influenza in Vellore District, Tamil Nadu, India |
|
|
301 | (16) |
|
|
|
|
301 | (2) |
|
|
303 | (4) |
|
3 Spatial Autoregressive Model |
|
|
307 | (4) |
|
|
311 | (2) |
|
|
313 | (4) |
|
|
314 | (3) |
|
13 Public Health Eye Care: Modeling Techniques to Translate Evidence Into Effective Action |
|
|
317 | (30) |
|
|
|
|
318 | (3) |
|
2 Magnitude of Blindness and Visual Impairment |
|
|
321 | (4) |
|
2.1 Calculating Global Magnitude and Current Prevalence of Blindness |
|
|
322 | (2) |
|
2.2 Calculating Incidence of Blindness and Visual Impairment |
|
|
324 | (1) |
|
3 Causes of Blindness and Visual Impairment |
|
|
325 | (7) |
|
3.1 Costing and Cost Analysis for Eye Care |
|
|
326 | (1) |
|
3.2 Use of Statistical Modeling for Cause-Specific Magnitude and Control Measures |
|
|
327 | (1) |
|
3.3 Forecasting the Need for Cataract Surgical Services |
|
|
328 | (4) |
|
4 Planning for Human Resource Needs for Future Eye Care Needs |
|
|
332 | (9) |
|
4.1 Developing a Model to Predict Requirement of Ophthalmologists for Control of Cataract Blindness: A Case Study From India |
|
|
334 | (7) |
|
|
341 | (6) |
|
|
342 | (5) |
|
14 Individual-Based Models for Public Health |
|
|
347 | (20) |
|
|
|
|
347 | (2) |
|
|
349 | (1) |
|
|
350 | (3) |
|
|
350 | (1) |
|
3.2 Unified Modeling Language and Individual-Based Modeling |
|
|
351 | (1) |
|
3.3 Toward a Formal Specification of IBMs by Using the Discrete Events Specification System |
|
|
351 | (2) |
|
4 Working With Mean-Field and Individual-Based Models |
|
|
353 | (1) |
|
4.1 IBMs and MFMs of the Same System |
|
|
353 | (1) |
|
4.2 The Coupling of IBM With MFM to Enable Scale Transfer Modeling (Multiscale Modeling) |
|
|
354 | (1) |
|
|
354 | (3) |
|
5.1 Spatially Explicit Models |
|
|
354 | (2) |
|
|
356 | (1) |
|
5.3 Multistrains Pathogens |
|
|
356 | (1) |
|
|
357 | (1) |
|
|
358 | (1) |
|
7 Biological Knowledge Gained Thanks to IBMs |
|
|
358 | (2) |
|
|
360 | (1) |
|
|
361 | (1) |
|
|
361 | (6) |
|
|
362 | (5) |
Index |
|
367 | |